Advanced stage cancer

Positive results from the phase 3 PAOLA-1 trial in women with advanced ovarian cancer. were announced. The trial, in the...


Several clinical trials studying mutIDH inhibitors in glioma and other solid tumors are ongoing or in planning stages and involve...


The European Commission ( EC ) has approved Keytruda , an anti-PD-1 therapy, as monotherapy or in combination with Platinum...


Results from the phase III IMbrave150 study evaluating Atezolizumab ( Tecentriq ) in combination with Bevacizumab ( Avastin ) were...


The FDA ( U.S. Food and Drug Administration ) has extended the indication of Ibrance ( Palbociclib ) capsules in...


The results for the pivotal phase II DESTINY-Breast01 trial of Trastuzumab deruxtecan ( DS-8201 ). The HER2-targeting antibody drug conjugate...


The US Food and Drug Administration ( FDA ) has approved Bavencio ( Avelumab ) in combination with Inlyta (...


The European Commission ( EC ) has approved Lynparza ( Olaparib ) as a 1st-line maintenance treatment for women with...


The European Commission has approved Talzenna ( Talazoparib ), an oral poly (ADP-ribose) polymerase ( PARP ) inhibitor, as monotherapy...


For patients with prostate cancer, treating the disease with androgen deprivation therapy ( ADT ) is linked to a...


Neoadjuvant, or pre-surgical, treatment with Nivolumab ( Opdivo ) plus Ipilimumab ( Yervoy ) resulted in an overall major pathologic...


The European Commission ( EC ) has approved Cabometyx ( Cabozantinib ) 20, 40, 60 mg for the first-line treatment...


Alectinib ( Alecensa ) has proven systemic and CNS efficacy in patients with ALK+ aNSCLC ( advanced non-small cell lung...


CheckMate 227, a phase 3 study of first-line Nivolumab ( Opdivo ) plus Ipilimumab ( Yervoy ), Nivolumab, or Nivolumab...


CheckMate 227 is a large phase 3 study of first-line Nivolumab plus Ipilimumab, Nivolumab, or Nivolumab plus chemotherapy vs chemotherapy...


The Committee for Medicinal Products for Human Use ( CHMP ) of the European Medicines Agency ( EMA ) has...



The FDA ( US Food and Drug Administration ) has approved Kisqali ( Ribociclib ) for women with hormone-receptor positive,...


The FDA ( U.S. Food and Drug Administration ) has approved Imfinzi ( Durvalumab ) for the treatment of patients...


The FDA ( U.S. Food and Drug Administration ) has approved Imfinzi ( Durvalumab ) for the treatment of patients...